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LOWER DOSE OF INTRAVENOUS IMMUNOGLOBULIN (I.V.IG) RESULTS IN
COMPARABLE OUTCOME IN CHILDREN WITH NEWLY DIAGNOSED ITP
Vineetha Raghavan, Chandran K. Nair, Anju R. Kurup. Malabar Cancer
Centre, Thalassery, India
Background: I.V.IG has been shown to be effective in Immune Thrombo-
cytopenia since 1981. The recommended dose is 0.4 g/kg/day for 5 days or
0.8 - 1 g/kg/day for 2 days. ASH 2011 guidelines say that a single dose of 0.8
- 1 g/kg of I.V.IG is also effective. But it has not become the standard of care
in all centres in India. At our centre we give single dose of 0.8- 1 g/kg
(capped off as per body weight) of I.V.IG to newly diagnosed acute ITP
patients who can afford the drug, and then check the response 48 hours
after the infusion. A second dose is administered only if there is no satis-
factory response with the ﬁrst dose. This mode of treatment helps in
reducing the cost of treatment and also the side effects of IVIG. With this
backgroundwe tried to assess the response to lower single dose of I.V.IG in
children with newly diagnosed ITP treated at MCC.
Method:Reviewofcasesheetsof6childrenwithnewlydiagnosed ITP treated
with I.V IG. For each patient, Baseline characteristics like Platelet count prior
to I.V.IG therapy, Presence of skin bleeds, Presence of mucosal bleeds were
noted. Immediate responsewasmeasuredbymeasuring theplatelet count48
hours after I.V.IG infusion. Response criteriawere chosen as per International
working group recommendations (Rodeghiero F et al, Blood 2009)
Result: 6 case ﬁles were reviewed. There were 2 girls and 4 boys. Out of
these six children who received single dose of 0.8 to 1 g/kg I.V.IG, half
required a second dose 48 hours later. Response to I.V.IG in these children
were as represented in table 1.Table 1
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Age/Sex 3 year/Male 5.5 years/Male 11 years/Male 3 years/Female 4.5 years/Male 10 years /Female
Baseline Platelet count (/mm3) 6000 14000 4000 9000 10000 10000
Skin bleeds at presentation (Yes/No) Yes Yes Yes Yes Yes Yes
Mucosal bleeds at presentation (Yes/No) Yes Yes No Yes No No
Duration of symptoms (days) 3 4 7 7 4 45
Platelet count 48 hours later (/mm3) 25000 83000 12000 21000 20000 44000
Resolution of bleeding symptoms at 48 hours Yes Yes Yes Yes Yes Yes
Second dose Required 48 hours after
ﬁrst dose (Yes/No)
No No Yes Yes Yes No
Platelet count 48 hours after second
dose of IVIG (/mm3)
NA NA 94000 31000 35000 NA
Quality of response CR CR R CR R R
Time to response (days) 261 8 4 46 4 1
Duration of follow up (days) 618 458 403 185 135 6
Duration of response (days) Still in CR Still in CR 11 Still in CR 12 Still in R
Side effects of I.V.IG therapy Fever, Shivering Fever None Fever None None“Complete response” (CR) is deﬁned as any platelet count of at least 100 
109/L. “Response” (R) is deﬁned as any platelet count between 30 and 100
 109/L and at least doubling of the baseline count. “No response” (NR) is
deﬁned as any platelet count lower than 30 109/L or less than doubling of
the baseline count.“Duration of the response” is calculated from the time of CR or R until loss
of CR or R.
Conclusion: Lower doses of IVIG is a cheaper but effective treatment op-
tion in children with newly diagnosed ITP in resource limited settings. We
could show that, if administered for one day alone the cost can be cut
down to half. Only those patients who do not respond to one dose need to
be administered a second dose.
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TO STUDY THE FACTORS AFFECTING QUALITY OF LIFE IN CHILDREN
SUFFERING FROM HEMOPHILIA
Mohammad Salmaan, Mamta Manglani, Maninder Sethia, Sujata
Sharma, R. Nikila, Sonia Karapurkar. Department of Pediatrics, Division of
Pediatric Hematology-Oncology, Lokmanya Tilak Municipal Medical College
and General Hospital, Sion, Mumbai, India
Background: Hemophilia is the most common severe bleeding disorder in
the world caused due to a single gene mutation. India has the second
largest number of Hemophilia patients in the world. Being a chronic dis-
ease, hemophilia has signiﬁcant impact on the quality of life which needs
to be assessed. This study was designed to assess the qol in children with
hemophilia and identify the factors that predict their qol, in order to better
plan and distribute the health care resources.
Material and Methods: This was a cross-sectional case control study
which included 30 children suffering from Hemophilia as cases and 30
normal healthy siblings' as controls aged between 5-12 years. The quality
of life assessment was performed using the Pediatric Quality of Life In-
ventory (PedsQoL) 4.0 Generic Core Scale. Two separate questionnaires
were administered for children between age group of 5 to 7 years and 8 to12 years. For the purpose of analysis Joint, Muscle and Intracranial bleeds
were together classiﬁed as Major bleeds, whereas skin and mucosal bleeds
as Minor bleeds. Data was analyzed using Stata Version 13. The means
between two groups were compared using the unpaired and paired t-test
(for different groups, and pre-and post-means respectively and Analysis of
